| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
ClearPoint Neuro (NASDAQ:CLPT) narrows FY2025 sales outlook from $36.000 million-$41.000 million to $36.000 million-$38.000 mil...
ClearPoint Neuro (NASDAQ:CLPT) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(...
ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering...
ClearPoint Neuro Inc. (NASDAQ:CLPT) shares are trading higher Wednesday after the company announced results from a Phase I-II c...
ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering...
The clearly established history across global regulatory bodies is expected to de-risk BioPharma partners' pathways towards...